ALSO NOTED: Jubilant buys generic company; NitroMed marketing BiDil; Aurobindo gets FDA nod for AIDS drug; and much more

> India's Jubilant Organosys has inked a deal to buy the U.S. generic drug company Trinity Laboratories and its wholly owned subsidiary Trigen Laboratories for $12.25 million. Story

> NitroMed has begun marketing BiDil for heart failure in black patients. Release

> India's Aurobindo Pharma has received tentative FDA approval for the generic AIDS drug efavirenz. Story

and finally...The FDA says that contrary to popular belief, green tea probably has little ability to prevent any kind of cancer. Article

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.